Grifols SA

ISIN US3984384087

 | 

WKN A1J1E2

Market cap (in EUR)
6,963 m
Country
Spain
Sector
Healthcare
Dividend yield
1.55%
 

Overview

Description

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.
Show more Show less
Healthcare Biopharmaceuticals Other Biopharmaceuticals Spain

Financials

Key metrics

Market capitalisation, EUR 6,963 m
EPS, EUR 0.56
P/B ratio 1.0
P/E ratio 15.0
Dividend yield 1.55%

Income statement (2024)

Revenue, EUR 7,212 m
Net income, EUR 157 m
Profit margin 2.18%

What ETF is Grifols SA in?

There is 1 ETF which contains Grifols SA.
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.10%
Equity
United States
Health Care
Biotech
44
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.